TITLE

Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial

AUTHOR(S)
Wharton, J. Marcus; Coleman, Diana Lewis; Wofsy, Constance B.; Luce, John M.; Blumenfeld, Walter; Hadley, W. Keith; Ingram-Drake, Leslie; Volberding, Paul A.; Hopewell, Philip C.; Wharton, J M; Coleman, D L; Wofsy, C B; Luce, J M; Blumenfeld, W; Hadley, W K; Ingram-Drake, L; Volberding, P A; Hopewell, P C
PUB. DATE
July 1986
SOURCE
Annals of Internal Medicine;Jul86, Vol. 105 Issue 1, p37
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Forty patients with the acquired immunodeficiency syndrome (AIDS) and their first episodes of Pneumocystis carinii pneumonia were assigned at random to receive either trimethoprim-sulfamethoxazole or pentamidine isethionate. The two groups did not differ significantly in the severity of pulmonary or systemic processes at enrollment. Five patients treated initially with trimethoprim-sulfamethoxazole and one patient treated initially with pentamidine died during the 21-day treatment period (p = 0.09, Fisher's exact test). No significant differences were seen between groups in rates of improvement, pulmonary function tests, or 67Ga uptake by the lungs in the survivors at completion of therapy. Adverse reactions necessitated changing from the initial drug in 10 patients in the trimethoprim-sulfamethoxazole group and 11 in the pentamidine group. Minor reactions occurred in all patients. In patients with AIDS, trimethoprim-sulfamethoxazole and pentamidine do not have statistically significant differences in efficacy or frequency of adverse reactions.
ACCESSION #
6998543

 

Related Articles

  • Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Sattler, Fred R.; Cowan, Robert; Nielsen, Donald M.; Ruskin, Joel; Sattler, F R; Cowan, R; Nielsen, D M; Ruskin, J // Annals of Internal Medicine;8/15/88, Vol. 109 Issue 4, p280 

    Study Objective: To ascertain the efficacy and toxicity of trimethoprim-sulfamethoxazole or pentamidine when either is given alone during the entire treatment period for Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome (AIDS).Design:...

  • Cotrimoxazole.  // Reactions Weekly;1/21/2017, Vol. 1635 Issue 1, p95 

    An abstract of the article "Successful treatment of severe Pneumocystis pneumonia in an immunosuppressed patient using caspofungin combined with clindamycin: A case report and literature review" by H. Li and others is presented.

  • Prophylaxis Recommendations for Pneumocystis. Dale, David C.; Federman, Daniel D. // Cortlandt Forum;3/25/2002, Vol. 15 Issue 3, p110 

    Reports the indication of primary prophylaxis of Pneumocystis for patients with history of Pneumocystis carinii pneumonia. Efficacy of trimethoprim-sulfamethoxazole (TMP-SMX); Considerations in discontinuing primary and secondary prophylaxis; Dosage for TMP-SMX.

  • Dapsone-Trimethoprim for Pneumonia in the Acquired Immunodeficiency Syndrome. Leoung, Clifford S.; Mills, John; Hopewell, Philip C.; Hughes, Walter; Wofsy, Constance // Annals of Internal Medicine;Jul86, Vol. 105 Issue 1, p45 

    Presents a study that examined the efficacy of dapsone plus trimethoprim for the treatment of patients with AIDS and a first episode of Pneumocystis carinii pneumonia. Methodology; Characteristics of patients with AIDS and Pneumocystis carinii pneumonia treated with dapsone-trimethoprim;...

  • Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. Helweg-Larsen, Jannik; Benfield, Thomas; Atzori, Chiara; Miller, Robert F. // Journal of Antimicrobial Chemotherapy (JAC);Dec2009, Vol. 64 Issue 6, p1282 

    Objectives: First-line therapy for Pneumocystis jirovecii pneumonia (PCP) is trimethoprim/sulfamethoxazole. Few data exist to guide the choice of second-line therapy for patients failing or developing toxicity to first-line therapy.

  • Clindamycin/tacrolimus interaction.  // Reactions Weekly;10/2/2010, Issue 1321, p14 

    The article describes the case of a woman who experienced decreased serum tacrolimus concentrations after starting clindamycin to treat Pneumocystis carinii (P. jirovecii) pneumonia.

  • Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis carinii Pneumonia. Winston, Drew J.; Lau, William K.; Gale, Robert Peter; Young, Lowell S. // Annals of Internal Medicine;Jun80, Vol. 92 Issue 6, p762 

    Presents a study which evaluated trimethoprim-sulfamethoxazole for the treatment of patients with Pneumocystis carinii pneumonia. Background on the clinical data of patients involved in the study; Comparison of clinical responses and side effects associated with trimethoprim-sulfamethoxazole...

  • Acute Megaloblastic Anemia Induced by High-Dose Trimethoprim-Sulfamethoxazole. Kobrinsky, Nathan; Ramsay, Norma K.C. // Annals of Internal Medicine;Jun81, Vol. 94 Issue 6, p780 

    Presents a case study of the development of acute megaloblastic anemia in a 22-year-old woman after treatment with high-dose trimethoprim-sulfamethoxazole for pneumocystis pneumonia. Background on the therapeutic applications of trimethoprim-sulfamethoxazole; Medical history of the patient;...

  • Questions Regarding the Effectiveness of Trimethoprim-Sulfamethoxazole (Cotrimoxazole) Prophylaxis in African Children. Gill, Christopher J.; Hamer, Davidson; Thea, Donald M. // Clinical Infectious Diseases;9/15/2003, Vol. 37 Issue 6, p863 

    Presents a letter to the editor in the September 15, 2003 issue of 'Clinical Infectious Diseases,' regarding the article 'Ineffectiveness of trimethoprime-sulfamethoxazole prophylaxis and the importance of bacterial and viral coinfections in African children with Pneumocystis carinii...

Share

Other Topics